Medication info
Nustatin AL Tablet 20 mg (Rosuvastatin Calcium)

Nustatin AL Tablet 20 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
Domestic use - 30 tablets/box [10 tablets/PTP*3], Domestic use - 100 tablets/bottle, Export use - 28 tablets/box [14 tablets/PTP*2]
Approval status
Active

MFDS item code 201401266 · Approved 2014.03.19 · Insurance code 647803960

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and reduction of cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams once daily. 3. Older patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. This medicine should not be used in patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with use in patients with a Child-Pugh score greater than 9. This medicine should not be used in patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Doses should be adjusted at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and reduction of cardiovascular disease risk

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • dyslipidemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used as an adjunct in cases where hypercholesterolemia and hyperlipidemia are difficult to manage through diet or exercise. It is effective for various types of hyperlipidemia, including primary hypercholesterolemia, familial hypercholesterolemia, and dysbetalipoproteinemia. Specifically, it lowers levels of LDL-cholesterol and total cholesterol, delaying the progression of cardiovascular disease, and is also helpful for pediatric patients with elevated LDL-cholesterol levels. Additionally, this medication improves cardiovascular health by reducing the risk of stroke, myocardial infarction, and vascular revascularization in patients at high risk for coronary artery disease. Overall, it helps to control cholesterol levels and reduce the risk of cardiovascular disease, thus improving the health status of patients.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams once daily. 3. Older patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. This medicine should not be used in patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with use in patients with a Child-Pugh score greater than 9. This medicine should not be used in patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Doses should be adjusted at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, patients who are allergic to any ingredients of this medication, have liver dysfunction, have muscle diseases, severely impaired kidney function, or are pregnant or breastfeeding should not take this medication. Additionally, the high-dose use of this medication is contraindicated in patients at risk for myopathy or rhabdomyolysis. Risk factors include moderate to severe kidney impairment, hypothyroidism, a family history of genetic muscular disorders, and alcoholism. This medication contains lactose, so patients with lactose intolerance should also avoid using it. Before administration, liver function tests and muscle-related tests should be conducted, and regular monitoring should continue during treatment. If symptoms such as muscle pain, weakness, fatigue, or fever occur, notify healthcare personnel immediately. This medication may interact with other drugs, so inform healthcare personnel of any other medications currently being taken, especially in combination with fibrates, cyclosporine, and certain antiviral agents. Women of childbearing potential should use appropriate contraceptive methods and avoid taking this medication while pregnant or breastfeeding. In case of overdose, there is no specific antidote, and treatment should be managed based on symptoms along with liver and muscle function tests. Caution is advised due to the possibility of dizziness when driving or operating machinery. Finally, if severe rash or allergic reactions occur while taking this medication, discontinue immediately and consult healthcare personnel.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ophthalmoplegia, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), drug-induced scaly erythema, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, paresthesia, chest discomfort, appetite loss, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a closed container to prevent air and moisture from entering. It should be stored at room temperature, between 1 and 30 degrees Celsius, and not in excessively hot or cold conditions.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

Domestic use - 30 tablets/box [10 tablets/PTP*3], Domestic use - 100 tablets/bottle, Export use - 28 tablets/box [14 tablets/PTP*2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.